The newly expanded RSV vaccination programme should reduce hospital admissions and better protect vulnerable patients ...
Results of a phase 2 study demonstrate that vixarelimab may be a promising therapy option for adults with moderate to severe prurigo nodularis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results